On behalf of Sage shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and ...

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sage Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Compugen (CGEN), finished the last trading session 0.6% higher at $1.65.

Inland Empire residents stock up on supplies as imports expected to shrink Next week, incoming cargo volume to the U.S. from China is expected to drop, according to the Port of Los Angeles.

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where Sage Therapeutics, Inc.

"A prisoner’s incredible skills lead to the design of an iconic M1 Carbine rifle. Rated Red is your go-to channel for everything Heartland! From epic food and cars to military life, video games ...

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

"A prisoner’s incredible skills lead to the design of an iconic M1 Carbine rifle. Rated Red is your go-to channel for everything Heartland! From epic food and cars to military life, video games ...

Shares of SAGE stock opened at $6.49 on Wednesday. The company’s fifty day moving average price is $7.81 and its 200-day moving average price is $11.02. Sage Therapeutics has a 12 month low of ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said it would cease development of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s ...

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Sage Therapeutics, Inc.